Latest news and press releases about Foghorn Therapeutics Inc. (FHTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system.
Price
| Price | $4.17 |
| Market Cap | $245M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -3.63 |
| EV / EBITDA | -3.75 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 72.64% |
| Return on Invested Capital | -44.00% |
| Return on Assets | -31.75% |
| Gross Margin | 42.73% |
| Operating Margin | -186.38% |
| Net Margin | -175.78% |
Related companies: ARCT · ASMB · ENTA · HUMA · IMRX · PYXS · SGMT
Explore sector: Healthcare · Biotechnology
More sections of FHTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks